Stock Price
85.81
Daily Change
5.15 6.38%
Monthly
30.53%
Yearly
13.49%
Q4 Forecast
74.95

EPS Reference Time Actual Consensus Previous
2026-07-29 FY2026Q2 1.24 1.19 1.06
2026-04-29 FY2026Q1 0.85 1.08 1.23
2026-02-04 FY2025Q4 1.29 1.41 1.57
2025-10-29 FY2025Q3 0.98 1.17
2025-07-30 FY2025Q2 1.06 1.15



Peers Price Chg Day Year Date
Supermax Corporation Bhd 0.46 -0.02 -4.17% 1.10% Nov/05
Hoya 24,075.00 -340.00 -1.39% -6.05% Nov/05
Ambu A/S 85.95 3.50 4.25% 3.37% Nov/04
Amplifon 11.76 0.02 0.17% -19.71% Nov/04
Apollo Hospitals Enterprise Ltd 8,325.00 -274.50 -3.19% 6.98% Nov/05
Brookdale Senior Living 11.19 0.82 7.91% 20.71% Nov/04
Coloplast 522.80 27.10 5.47% -14.96% Nov/04
Cencora 354.00 13.50 3.96% 0% Nov/04
Convatec Group 254.00 10.40 4.27% 4.70% Nov/04
Diasorin 82.18 1.78 2.21% 10.67% Nov/04

Indexes Price Day Year Date
US Index 500 7679 119.70 1.58% 14.26% Nov/05
US Index 100 28143 256.91 0.91% 11.99% Nov/05

GE HealthCare Technologies traded at $85.81 this Wednesday November 4th, increasing $5.15 or 6.38 percent since the previous trading session. Looking back, over the last four weeks, GE HealthCare Technologies gained 30.53 percent. Over the last 12 months, its price rose by 13.49 percent. Looking ahead, we forecast GE HealthCare Technologies to be priced at 74.95 by the end of this quarter and at 70.28 in one year, according to Trading Economics global macro models projections and analysts expectations.

GE HealthCare Technologies Inc. is a medical technology, pharmaceutical diagnostics, and digital solutions company. The Company provides integrated solutions, services, and data analytics. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. The segment also includes the clinical artificial intelligence (AI) software business. Its PCS segment portfolio consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment consists of two business lines: contrast media and molecular imaging.